{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:27:54Z","timestamp":1773746874792,"version":"3.50.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cancer and death are the most severe outcomes that affect patients with inflammatory bowel disease (IBD). These outcomes are even more severe if they occur at a young age but are rare, even in the general population. We conducted a systematic review to provide an overview of all reported pediatric (PIBD) patients with severe outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A literature search identified publications that reported development of cancer or fatal outcome in PIBD patients. Studies were eligible for inclusion when (1) article written in English, (2) original data, (3) individual patient information, (4) full text available, (5) study population consisting of patients diagnosed with IBD under the age of 19 years, and (6) who developed malignancy or fatality at any point later in life.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 98 included studies comprised data of 271 PIBD patients who developed cancer and\/or fatal outcome at any point later in life. Meta-analysis demonstrated an increased risk for cancer in PIBD patients (pooled standardized incidence ratio 2.23, 95% CI: 1.98\u20132.52). The most frequent type of non-fatal cancer was lymphoma, whereas colorectal carcinomas were the most frequently reported type of fatal cancer in PIBD patients and were particularly associated with primary sclerosing cholangitis. The majority of patients with noncancer-related fatal outcomes were diagnosed with ulcerative colitis and most often died due to infectious complications or severe disease-associated complications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The data in this review confirm that PIBD associated malignancy and mortality are rare and detailed clinical characteristics are limited. Prospective and international collaborations are needed to obtain more detailed patient-specific information, which is necessary to investigate the relationship between severe outcomes in PIBD patients and the currently used therapeutic strategies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izx104","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T10:54:56Z","timestamp":1520420096000},"page":"732-741","source":"Crossref","is-referenced-by-count":40,"title":["Malignancy and Mortality in Pediatric-onset Inflammatory Bowel Disease: A Systematic Review"],"prefix":"10.1093","volume":"24","author":[{"given":"Martine A","family":"Aardoom","sequence":"first","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus MC-Sophia Children\u2019s Hospital, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E","family":"Joosse","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus MC-Sophia Children\u2019s Hospital, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrica C H","family":"de Vries","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Erasmus MC-Sophia Children\u2019s Hospital, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arie","family":"Levine","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, The Wolfson Medical Center, Tel-Aviv University, Tel-Aviv, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lissy","family":"de Ridder","sequence":"additional","affiliation":[{"name":"Department of Pediatric Gastroenterology, Erasmus MC-Sophia Children\u2019s Hospital, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"2020082409270316200_CIT0001","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/ibd.21797","article-title":"Rising incidence of pediatric inflammatory bowel disease in scotland","volume":"18","author":"Henderson","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"2020082409270316200_CIT0002","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/ibd.21550","article-title":"Incidence trends of pediatric inflammatory bowel disease in finland, 1987-2003, a nationwide study","volume":"17","author":"Lehtinen","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2020082409270316200_CIT0003","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ibd.22980","article-title":"Increasing incidence of pediatric inflammatory bowel disease in Spain (1996\u20132009): the SPIRIT Registry","volume":"19","author":"Martin-de-Carpi","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"2020082409270316200_CIT0004","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1053\/j.gastro.2013.04.007","article-title":"Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn\u2019s and colitis epidemiology study","volume":"145","author":"Ng","year":"2013","journal-title":"Gastroenterology"},{"key":"2020082409270316200_CIT0005","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1053\/j.gastro.2008.06.081","article-title":"Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease","volume":"135","author":"Van Limbergen","year":"2008","journal-title":"Gastroenterology"},{"key":"2020082409270316200_CIT0006","doi-asserted-by":"crossref","first-page":"e509","DOI":"10.1016\/j.crohns.2013.03.007","article-title":"Presenting features and disease course of pediatric ulcerative colitis","volume":"7","author":"Aloi","year":"2013","journal-title":"J Crohns Colitis"},{"key":"2020082409270316200_CIT0007","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1053\/j.gastro.2008.06.079","article-title":"Natural history of pediatric crohn\u2019s disease: a population-based cohort study","volume":"135","author":"Vernier-Massouille","year":"2008","journal-title":"Gastroenterology"},{"key":"2020082409270316200_CIT0008","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1002\/ibd.21152","article-title":"Natural history of crohn\u2019s disease: comparison between childhood- and adult-onset disease","volume":"16","author":"Pigneur","year":"2010","journal-title":"Inflamm Bowel Dis"},{"key":"2020082409270316200_CIT0009","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.29.2.206","article-title":"Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres","volume":"29","author":"Gyde","year":"1988","journal-title":"Gut"},{"key":"2020082409270316200_CIT0010","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJM199011013231802","article-title":"Ulcerative colitis and colorectal cancer. a population-based study","volume":"323","author":"Ekbom","year":"1990","journal-title":"N Engl J Med"},{"key":"2020082409270316200_CIT0011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cgh.2012.09.026","article-title":"Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010","volume":"11","author":"Jess","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020082409270316200_CIT0012","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.cgh.2015.02.017","article-title":"Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in crohn\u2019s disease","volume":"13","author":"Osterman","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020082409270316200_CIT0013","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/ecco-jcc\/jjv190","article-title":"Impact of new treatments on hospitalisation, surgery, infection, and mortality in ibd: a focus paper by the epidemiology committee of ecco","volume":"10","author":"Annese","year":"2016","journal-title":"J Crohns Colitis"},{"key":"2020082409270316200_CIT0014","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"2020082409270316200_CIT0015","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020082409270316200_CIT0016","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"2020082409270316200_CIT0017","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ajg.2013.451","article-title":"Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis","volume":"109","author":"Ariyaratnam","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"2020082409270316200_CIT0018","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/MIB.0000000000000338","article-title":"Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia\/cancer? a meta-analysis","volume":"21","author":"Allegretti","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"2020082409270316200_CIT0019","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Cottone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020082409270316200_CIT0020","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/2040622310368736","article-title":"The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel disease","volume":"1","author":"O\u2019Connor","year":"2010","journal-title":"Ther Adv Chronic Dis"},{"key":"2020082409270316200_CIT0021","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.cgh.2014.01.021","article-title":"Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review","volume":"12","author":"Dulai","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2020082409270316200_CIT0022","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the prisma statement","volume":"6","author":"Moher","year":"2009","journal-title":"Plos Med"},{"key":"2020082409270316200_CIT0023","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/ibd.20845","article-title":"Long-term outcome of maintenance infliximab therapy in children with crohn\u2019s disease","volume":"15","author":"Hyams","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"2020082409270316200_CIT0024","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1053\/j.gastro.2017.02.004","article-title":"Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease","volume":"152","author":"Hyams","year":"2017","journal-title":"Gastroenterology"},{"key":"2020082409270316200_CIT0025","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1155\/2004\/101097","article-title":"Long-term prognosis of early-onset crohn\u2019s disease diagnosed in childhood or adolescence","volume":"18","author":"Freeman","year":"2004","journal-title":"Can J Gastroenterol"},{"key":"2020082409270316200_CIT0026","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/gut.25.4.329","article-title":"Long term prognosis of crohn\u2019s disease with onset in childhood and adolescence","volume":"25","author":"Puntis","year":"1984","journal-title":"Gut"},{"key":"2020082409270316200_CIT0027","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/MEG.0b013e32832a4ed6","article-title":"Paediatric inflammatory bowel disease during a 44-year period in copenhagen county: occurrence, course and prognosis\u2013a population-based study from the danish crohn colitis database","volume":"21","author":"Jakobsen","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2020082409270316200_CIT0028","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1097\/01.MIB.0000439066.69340.3c","article-title":"Malignancy and mortality in pediatric patients with inflammatory bowel disease: a multinational study from the porto pediatric ibd group","volume":"20","author":"de Ridder","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"2020082409270316200_CIT0029","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1002\/art.27511","article-title":"Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the food and drug administration","volume":"62","author":"Diak","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2020082409270316200_CIT0030","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1038\/ajg.2013.242","article-title":"Mortality and cancer in pediatric-onset inflammatory bowel disease: a population-based study","volume":"108","author":"Peneau","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2020082409270316200_CIT0031","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1053\/j.gastro.2012.04.054","article-title":"Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010","volume":"143","author":"Herrinton","year":"2012","journal-title":"Gastroenterology"},{"key":"2020082409270316200_CIT0032","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/gut.48.4.526","article-title":"The risk of colorectal cancer in ulcerative colitis: a meta-analysis","volume":"48","author":"Eaden","year":"2001","journal-title":"Gut"},{"key":"2020082409270316200_CIT0033","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/apt.12651","article-title":"Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis","volume":"39","author":"Casta\u00f1o-Milla","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2020082409270316200_CIT0034","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ajg.2016.55","article-title":"Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and ibd","volume":"111","author":"Gulamhusein","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2020082409270316200_CIT0035","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1002\/hep.26565","article-title":"Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis","volume":"58","author":"Boonstra","year":"2013","journal-title":"Hepatology"},{"key":"2020082409270316200_CIT0036","doi-asserted-by":"crossref","first-page":"j3951","DOI":"10.1136\/bmj.j3951","article-title":"Childhood onset inflammatory bowel disease and risk of cancer: a swedish nationwide cohort study 1964-2014","volume":"358","author":"Ol\u00e9n","year":"2017","journal-title":"Bmj"},{"key":"2020082409270316200_CIT0037","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.dld.2016.07.008","article-title":"Total and cancer mortality in a cohort of ulcerative colitis and crohn\u2019s disease patients: the florence inflammatory bowel disease study, 1978-2010","volume":"48","author":"Caini","year":"2016","journal-title":"Dig Liver Dis"},{"key":"2020082409270316200_CIT0038","unstructured":"Ol\u00e9n\n              O. AJ\n            , SachsMC, FrumentoP, et al\n          Mortality in childhood-onset inflammatory bowel disease - a population-based cohort study spanning 50 years. ESPGHAN Annual Meeting. 2017. 2017:G-eP-053."},{"key":"2020082409270316200_CIT0039","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1572-0241.2006.01000.x","article-title":"Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies","volume":"102","author":"Jess","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"2020082409270316200_CIT0040","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ajg.2012.89","article-title":"a pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"2020082409270316200_CIT0041","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"hlh-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"2020082409270316200_CIT0042","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"2020082409270316200_CIT0043","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/ibd.21582","article-title":"Risk of malignant lymphoma in patients with inflammatory bowel diseases: a dutch nationwide study","volume":"17","author":"Vos","year":"2011","journal-title":"Inflamm Bowel Dis"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/24\/4\/732\/33677819\/izx104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/24\/4\/732\/33677819\/izx104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T13:27:17Z","timestamp":1598275637000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/24\/4\/732\/4924482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":43,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,3,7]]},"published-print":{"date-parts":[[2018,3,19]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izx104","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,4]]},"published":{"date-parts":[[2018,3,7]]}}}